News

Upon closing of the transaction, MabVax and Telik will be combined into a publicly traded company focused on the development of proprietary immunotherapy-based products to diagnose and treat

The 600-plus-page treatise was sent to Health Canada on 5 May 2014. The conditions that must be met before the issuance of a licence are understandably extensive due

The new therapy is indicated for the adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older. Perampanel

The NDA submission is based on positive and consistent results from two pivotal Phase III trials – REFINE-1 and REFINE-2. In these trials, which were reported in late

Patent applications covering similar claims have issued in Canada and are under review in the US. Preliminary human and animal studies indicate that AAT may considerably reduce the

The company said it will work closely work with the FDA in accelerating its development program for CVac to potentially bring this treatment option to patients in the

University of Northern Colorado professor of Chemistry and Biochemistry and member of the Scientific Advisory Board at Medical Marijuana Sciences, a wholly owned subsidiary of Nuvilex, Richard Hyslop

Located adjacent to CSL Behring’s manufacturing plant for plasma products, the new facility is the centerpiece of the company’s $250m expansion at its Broadmeadows site and will play

The company has introduced 0.25mg, 0.5mg, 1mg, 2mg, 3mg and 4mg doses of the Risperidone Tablets, which are used to treat schizophrenia and bipolar disorder. According to IMS